The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204)

S.F. Altekruse, C.L. Kosary, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, J. Ruhl, N. Howlader, Z. Tatalovich, H. Cho, A. Mariotto, M.P. Eisner, D.R. Lewis, K. Cronin, H.S. Chen, E.J. Feuer, D.G. Stinchcomb, B.K. Edwards (Eds.), SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. Hundahl, 1998, A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985–1995, Cancer, 83, 2638, 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1 Xing, 2005, BRAF mutation in thyroid cancer, Endocr. Relat. Cancer, 12, 245, 10.1677/erc.1.0978 Xing, 2007, BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications, Endocr. Rev., 742, 10.1210/er.2007-0007 Tang, 2010, BRAF mutation in papillary thyroid carcinoma: pathogenic role and clinical implications, J. Chin. Med. Assoc., 73, 113, 10.1016/S1726-4901(10)70025-3 Li, 2010, Recent advances in the research and development of B-Raf inhibitors, Curr. Med. Chem., 17, 1618, 10.2174/092986710791111242 Smalley, 2010, PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma, Curr. Opin. Invest. Drugs, 11, 699 Tsai, 2008, Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity, Proc. Natl. Acad. Sci. USA, 105, 3041, 10.1073/pnas.0711741105 Joseph, 2010, The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner, Proc. Natl. Acad. Sci. USA, 107, 14903, 10.1073/pnas.1008990107 Flaherty, 2010, Inhibition of mutated, activated BRAF in metastatic melanoma, N. Engl. J. Med., 363, 809, 10.1056/NEJMoa1002011 Bollag, 2010, Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma, Nature, 467, 596, 10.1038/nature09454 Welkos, 1994, Determination of median lethal and infectious doses in animal model systems, Methods Enzymol., 235, 29, 10.1016/0076-6879(94)35128-7 Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 Casado, 2007, Molecular markers in colorectal cancer: genetic bases for a customised treatment, Clin. Transl. Oncol., 9, 549, 10.1007/s12094-007-0102-8 Chang, 2009, Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy, J. Hematol. Oncol., 2, 18, 10.1186/1756-8722-2-18 Heist, 2009, EGFR-targeted therapies in lung cancer: predictors of response and toxicity, Pharmacogenomics, 10, 59, 10.2217/14622416.10.1.59 Xing, 2009, Genetic-targeted therapy of thyroid cancer: a real promise, Thyroid, 19, 805, 10.1089/thy.2009.1583 Salerno, 2010, Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells, J. Clin. Endocrinol. Metab., 95, 450, 10.1210/jc.2009-0373